share_log

FDA Selects Perspective Therapeutics To Participate In The CDRP Program To Expedite Chemistry, Manufacturing, and Controls Development Readiness For VMT-α-NET in Neuroendocrine Tumors

FDA Selects Perspective Therapeutics To Participate In The CDRP Program To Expedite Chemistry, Manufacturing, and Controls Development Readiness For VMT-α-NET in Neuroendocrine Tumors

FDA選擇Persective Therapeutics參與CDRP計劃,以加快神經內分泌腫瘤中VMT-α-Net的化學、製造和控制開發準備工作
Benzinga ·  04/30 19:20

FDA Selects Perspective Therapeutics To Participate In The CDRP Program To Expedite Chemistry, Manufacturing, and Controls Development Readiness For VMT-α-NET in Neuroendocrine Tumors

FDA選擇Persective Therapeutics參與CDRP計劃,以加快神經內分泌腫瘤中VMT-α-Net的化學、製造和控制開發準備工作

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論